Rabies glycoprotein virus-like particles (VLPS)

Patent metadata

Field	Value
Publication number	US-9724405-B2
Application number	US-201113883745-A
Country	US
Kind code	B2
Filing date	Nov 7, 2011
Priority date	Nov 5, 2010
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising rabies virus (RV) glycoproteins (G proteins) in a micellar particle with NP-9, wherein the G proteins form a trimer, wherein the G proteins are purified from an insect host cell, and a pharmaceutically acceptable carrier, diluent, or excipient.

2. The pharmaceutical composition of claim 1 , wherein the RV G protein comprises SEQ ID NO:2.

3. The pharmaceutical composition of claim 1 , wherein the RV G proteins are derived from an RV strain selected from human, canine, bat, raccoon, skunk, and fox.

4. The pharmaceutical composition of claim 1 , further comprising an adjuvant.

5. The pharmaceutical composition of claim 4 , wherein the adjuvant is an aluminum adjuvant.

6. The pharmaceutical composition of claim 1 , wherein the micellar particle increases the production of anti-G protein antibodies in a host.

7. The pharmaceutical composition of claim 6 , wherein the anti-G protein antibodies produced are neutralizing antibodies.

8. The pharmaceutical composition of claim 7 , wherein the anti-G protein antibodies produced are protective.

9. The pharmaceutical composition of claim 6 , wherein the micellar particle induces the production of anti-G protein antibodies in the host after administration of a single dose.

10. The pharmaceutical composition of claim 6 , wherein the micellar particle provides a seroprotective titer in 7 days.

11. A method of treating or preventing a rabies infection comprising administering to a host a micellar particle comprising rabies virus (RV) glycoproteins (G proteins), wherein the G proteins form a trimer, and wherein the micellar particles are purified from an insect host cell and comprises the detergent NP-9.

12. The method of claim 11 , wherein the micellar particle increases the production of anti-G protein antibodies in the host.

13. The method of claim 12 , wherein the anti-G protein antibodies produced are neutralizing antibodies.

14. The method of claim 13 , wherein the anti-G protein antibodies produced are protective.

15. The method of claim 12 , wherein the micellar particle induces the production of anti-G protein antibodies in the host after administration of a single dose.

16. The method of claim 12 , wherein the micellar particle provides a seroprotective titer in 7 days.

17. A method of making a micellar particle comprising rabies virus (RV) glycoproteins (G proteins), wherein the G proteins form a trimer comprising:
(a) transforming an insect host cell to express an isolated nucleic acid encoding a RV G protein; and
(b) culturing said host cell under conditions conducive to the production of said micellar particle; and
(c) purifying the micellar particle in the presence of the detergent NP-9.

18. The pharmaceutical composition of claim 1 wherein the insect cell is an Sf9 cell.

Assignees

• Smith Gale
• Liu Ye
• Novavax Inc

Inventors

• Smith Gale
• Liu Ye

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title